Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

BACKGROUND: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous interferon beta-1a (SC IFNB-1a) in relapsing–remitting multiple sclerosis patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072102/
https://www.ncbi.nlm.nih.gov/pubmed/34035833
http://dx.doi.org/10.1177/1756286420982134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072102/
https://www.ncbi.nlm.nih.gov/pubmed/34035833
http://dx.doi.org/10.1177/1756286420982134

Ejemplares similares